Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
52-week ₹108.71 – ₹277.57 · ADTV ₹34.2 cr · price-only.
Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ